Home > Europe > United Kingdom > United Kingdom Patient Content

Information About Molnupiravir ▼ 

The information on this page is intended for the Patient or Carer only

Reporting of suspected adverse reactions

Reporting side effects: if you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://coronavirus-yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.

This link will take you to a third-party website. MSD do not review or control the content of any third-party site. We do not endorse and are not responsible for the accuracy, content, practices or standards of any third-party sources.

Electronic Medicines Compendium and Patient Information Leaflet

You can visit the electronic Medicines Compendium website to access the Patient Information Leaflet for Molnupiravir. This link will take you to a third-party website. MSD provides this link as a service to website visitors. MSD is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

The MHRA has issued a Conditional Marketing Authorisation for Lagevrio (molnupiravir) in Great Britain and a temporary Regulation 174 authorisation for Northern Ireland to ensure supply across all of the UK.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://coronavirus-yellowcard.mhra.gov.uk for how to report side effects.

GB-ANV-00003 | Date of Preparation: November 2021